ATN-161 acetate, a pentapeptide compound derived from the synergistic region of fibronectin, is a non-competitive integrin-alpha5 antagonist with antitumor activity that attenuates the pathology of caerulein-induced acute pancreatitis.

The treatment regimen of ATN-161 acetate in combination with 5-FU was able to significantly inhibit the proliferation of tumor cells compared to control and monotherapy. In addition, the combination treatment significantly increased the proportion of TUNEL-positive tumor cells, while monotherapy failed to increase TUNEL-positive cells. ATN-161 acetate significantly reduced the number of cancer cells after 48 hours of culture (21% reduction) compared to the control group. [1]
ATN-161 acetate prevented vascular endothelial growth factor-induced migration and capillary formation of hCECs, but had no significant effect on proliferation. Starting at 100 nM, ATN-161 acetate decreased the number of cells migrating in response to VEGF in a dose-dependent manner (compared to the VEGF group). [2]

Injection of ATN-161 acetate after laser photocoagulation reduced choroidal neovascularization (CNV) leakage and neovascularization with an inhibitory effect comparable to that of AF564. [2]